Abstract
Hematopoietic stem cell transplantation has evolved as a central treatment modality in the management of different hematologic malignancies. Despite adequate posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in the hematopoietic stem cell transplantation setting, even in patients who receive human leukemic antigen (HLA) identical sibling grafts. Up to 30% of the recipients of stem cells or bone marrow transplantation from HLA-identical related donors and most patients who receive cells from other sources (matched-unrelated, non-HLA-identical siblings, cord blood) will develop > Grade 2 acute GVHD despite immunosuppressive prophylaxis. Thus, GVHD continues to be a major limitation to successful hematopoietic stem cell transplantation. In this review, the authors summarize the most current knowledge on the pathophysiology, clinical manifestations, and management of this potentially life-threatening transplantation complication.
Original language | English (US) |
---|---|
Pages (from-to) | 1936-1946 |
Number of pages | 11 |
Journal | Cancer |
Volume | 101 |
Issue number | 9 |
DOIs | |
State | Published - Nov 1 2004 |
Externally published | Yes |
Keywords
- Hematopoietic stem cell transplantation
- Immunosuppressive therapy
- Inflammatory cytokines
- T-cell subsets
ASJC Scopus subject areas
- Cancer Research
- Oncology